Kcentra
Biological
CSL Behring
Total Payments
$56.0M
Transactions
36,456
Doctors
16,273
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $31.4M | 8,349 | 4,742 |
| 2023 | $15.5M | 7,364 | 4,550 |
| 2022 | $917,351 | 4,252 | 2,832 |
| 2021 | $1.6M | 3,290 | 2,029 |
| 2020 | $867,572 | 2,093 | 1,322 |
| 2019 | $2.5M | 4,111 | 2,263 |
| 2018 | $1.3M | 3,593 | 1,957 |
| 2017 | $2.0M | 3,404 | 2,048 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $50.8M | 2,007 | 90.7% |
| Honoraria | $1.9M | 669 | 3.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 408 | 2.9% |
| Food and Beverage | $892,896 | 28,281 | 1.6% |
| Travel and Lodging | $582,648 | 1,962 | 1.0% |
| Education | $72,184 | 3,107 | 0.1% |
| Consulting Fee | $67,885 | 19 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $3,500 | 1 | 0.0% |
| Gift | $26.50 | 2 | 0.0% |
Payments by Type
Research
$50.8M
2,007 transactions
General
$5.2M
34,449 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding | CSL Behring | $44.9M | 0 |
| An Observational Cohort Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding | CSL Behring | $1.7M | 0 |
| IISKCENTRA | CSL Behring | $1.0M | 0 |
| A Prospective Randomized Controlled Trial on Pre-Hospital Use of Kcentra in Trauma Patients with Hemorrhagic Shock | CSL Behring | $1.0M | 0 |
| A Prospective Randomized Prehospital Trial Comparing Kcentra Plus Standard of Care to Standard of Care Alone in Trauma Patient With Hemorrhagic Shock | CSL Behring | $500,000 | 0 |
| Risk of Thromboembolic Events Among Adults Treated with Kcentra vs. with Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding | CSL Behring | $410,742 | 0 |
| Prehospital Kcentra for Hemorrhagic Shock IIS Pilot Trial | CSL Behring | $400,000 | 0 |
| IIS KCENTRA | CSL Behring | $270,000 | 0 |
| Cost Effective Analysis of Kcentra in Management of Gastrointestinal Bleeding in Coumadin-Treated Patients | CSL Behring | $114,000 | 0 |
| Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center. | CSL Behring | $91,740 | 0 |
| Optimized Administration of Prothrombin Complex Concentrate (PCC) vs. Standard Transfusion During/After Heart Transplantation - OPSTAHT | CSL Behring | $48,280 | 0 |
| Administration of Prothrombin Complex Concentrate vs. Standard Transfusion DuringAfter Heart Transplantation OPSTAHT | CSL Behring | $42,744 | 0 |
| Assessment of COAG Levels in LVAD Patients Following Tem Warfarin Reversal with Kcentra | CSL Behring | $37,917 | 0 |
| BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services The BEST-MSU Study | CSL Behring | $37,477 | 0 |
| Optimized administration of Prothrombin complex concentrate PCC vs. Standard Transfusion duringafter Heart Transplantation - OPSTAHT | CSL Behring | $36,120 | 0 |
| Optimized Administration of Prothrombin Complex Concentrate PCC vs. Standard Transfusion DuringAfter Heart Transplantation - OPSTAHT | CSL Behring | $34,610 | 0 |
| BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services:The BEST-MSU Study | CSL Behring | $31,735 | 0 |
| Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal With 4F-PCC | CSL Behring | $30,313 | 0 |
| Prothrombin complex concentrate compared to fresh frozen plasma for post-cardiopulminary bypass coagulopathy and bleeding, a prospective randomized trial at large US medical center. | CSL Behring | $29,139 | 0 |
| Prothrombin Complex Concentrate PCC Compared to Fresh Frozen Plasma FFP for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center | CSL Behring | $23,207 | 0 |
Top Doctors Receiving Payments for Kcentra
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Virginia Beach, VA | $50.8M | 2,683 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Tacoma, WA | $617,864 | 584 |
| , MD | Emergency Medicine | Williamsville, NY | $499,451 | 504 |
| , M.D | Neurology | Tampa, FL | $463,728 | 459 |
| , MD | Anesthesiology | Louisville, KY | $343,060 | 395 |
| , M.D | Internal Medicine | Livingston, NJ | $302,953 | 277 |
| , MD | Surgery | Columbus, OH | $297,196 | 288 |
| , MD | Anesthesiology | Englewood, NJ | $285,897 | 250 |
| , MD | Emergency Medicine | Philadelphia, PA | $270,952 | 284 |
| , MD | Neurological Surgery | Dallas, TX | $229,131 | 193 |
| , DO | Specialist | Columbus, OH | $130,571 | 149 |
| , D.O | Personal Emergency Response Attendant | Scottsdale, AZ | $108,144 | 128 |
| , M.D | Internal Medicine | Albany, NY | $91,052 | 129 |
| , MD | Clinical Pathology | Rochester, NY | $75,842 | 69 |
| , MD | Emergency Medicine | Cleveland, OH | $58,196 | 79 |
| , MD | Neurology | Cincinnati, OH | $53,197 | 55 |
| , M.D | Neurology | Chicago, IL | $38,603 | 51 |
| , MD | Emergency Medical Services | Austin, TX | $34,114 | 12 |
| , MD | Clinical Pathology/Laboratory Medicine | Atlanta, GA | $33,514 | 49 |
| , MD | Hematology & Oncology | Philadelphia, PA | $30,501 | 4 |
| , MD, PHD | Emergency Medicine | Boston, MA | $25,792 | 18 |
| John Holcomb | Trauma Surgery | Houston, TX | $20,481 | 18 |
| , MD | Blood Banking & Transfusion Medicine | Dallas, TX | $17,920 | 5 |
| Jan Jansen | Trauma Surgery | Birmingham, AL | $17,816 | 6 |
| , MD | Surgery | Portland, OR | $16,764 | 25 |
Ad
Manufacturing Companies
- CSL Behring $56.0M
Product Information
- Type Biological
- Total Payments $56.0M
- Total Doctors 16,273
- Transactions 36,456
About Kcentra
Kcentra is a biological associated with $56.0M in payments to 16,273 healthcare providers, recorded across 36,456 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2024. In 2024, $31.4M was paid across 8,349 transactions to 4,742 doctors.
The most common payment nature for Kcentra is "Unspecified" ($50.8M, 90.7% of total).
Kcentra is associated with 20 research studies, including "A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding" ($44.9M).